UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Mulling biopharma’s Minority Report moment
Amgen might yet prevail in its attempt to buy Horizon, but the FTC shockwaves will still be felt.
Heightened US antitrust fears rattle biopharma
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
Pfizer's fortunes overshadow first-quarter dealmaking
Aside from Seagen, small takeouts dominate the first quarter.
Biopharma stocks go back to bleak
Hopes for a better 2023 look optimistic as markets take another turn for the worse.
Go or no go? Seagen's Padcev eyes FDA approval
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.